ImmunoBrain Checkpoint

Executive Summary

ImmunoBrain Checkpoint is an Israeli biotechnology company pioneering a novel approach to treat neurodegenerative diseases by targeting the peripheral immune system. Unlike traditional CNS-focused therapies, the company leverages insights into brain-immune communication to modulate neuroinflammation, a key driver of Alzheimer’s disease pathology. Its lead candidate, IBC-Ab002, is a monoclonal antibody against PD-L1 designed to activate peripheral immune cells, enabling them to clear amyloid plaques and mitigate neuroinflammation without entering the brain. Currently in a Phase 1 clinical trial for early Alzheimer’s disease, IBC-Ab002 represents a first-in-class therapy that could address the significant unmet need in Alzheimer’s treatment. The company’s unique platform holds potential for other neurodegenerative conditions, positioning it as a disruptive player in the neuroimmunology space. However, the approach remains unvalidated in humans, and the early stage of development presents substantial clinical and regulatory risks.

Upcoming Catalysts (preview)

• Q4 2026Phase 1 interim safety and biomarker data readout35% success
• H1 2027FDA feedback or IND update for next indication30% success
• 2026-2027Potential partnership or Series B financing50% success